ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1494

Determinants of Clinically Important Worsening in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort over 5 Years

Faten Hamitouche1, Sushmitha Kumaradev1, Désirée van der Heijde2, Sofia Ramiro3, Alexandre Sepriano4 and Anna Molto5, 1INSERM U-1153, Université Paris-Cité, CRESS, Paris, France, 2Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 3Leiden University Medical Center, Leiden, Netherlands, 4Leiden University Medical Centre, Portela Loures, Portugal, 5Rheumatology Department, Hôpital Cochin,Assistance Publique- Hôpitaux de Paris, Paris, France

Meeting: ACR Convergence 2022

Keywords: spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: A definition for clinically important worsening (CIW) of axial Spondyloarthritis (axSpA) has been proposed by ASAS: i.e. an increase of ≥0.9 points of ASDAS. However, it is unknown how this definition performs in an early axSpA cohort.

The aim of this study was to determine the prevalence of CIW in a population of early axSpA, as well as the association between the occurrence of CIW and the presence of concomitant signs of inflammation; finally, to determine whether MRI inflammation was predictive of a future CIW.

Methods: 708 patients with early axSpA from the French DESIR cohort were included in the analysis. Patients were followed every 6 months for the first 2 years and annually thereafter. All patients had an MRI of spine and sacroiliac joints at baseline, but only patients from the APHP centers performed those at 2 and 5 years. Prevalence of CIW was calculated during the 5 years of follow-up in the cohort. The association between CIW and concomitant objective signs of inflammation (such as swollen joint count) was assessed over time using mixed models adjusted for sociodemographic and other clinical covariates. CIW predictive factors including the predictive capacity of MRI inflammation (measured by SPARCC at SIJ and spine) and MRI structural damage (defined by presence of ≥5 structural lesions of SI joints or spine) on the occurrence of a future CIW (time-lagged models) were evaluated.

Results: Total number of CIW was 378 in 5 years with 42.8% (303/708) of patients presenting at least one CIW during the follow-up. There were no significant sociodemographic or clinical differences at inclusion between patients with at least one episode of CIW and those without CIW during follow-up.

In the association models, concomitant tender joint count (OR 1.02, CI95%[1.00; 1.03]) and ASAS-NSAID score last week (OR 1.00, CI95%[1.00; 1.01]) were significantly associated with CIW over time. Presence of MRI-SIJ inflammation (OR (per SPARCC point) 1.02, CI95%[1.01; 1.04]) and MRI-SIJ structural damage (OR 2.74, CI95%[1.27; 5.93]) were predictive of future (next visit) occurrence of CIW.

Conclusion: Patients with CIW according to the ASAS definition had significantly more objective signs of inflammation concomitantly but also over time. These data support the construct validity of this definition of CIW in an early axSpA population. MRI-SIJ inflammation and structural damage may have a predictive role in the subsequent occurrence of CIW.

Supporting image 1

Supporting image 2


Disclosures: F. Hamitouche, None; S. Kumaradev, None; D. van der Heijde, AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Novartis, Pfizer, UCB, Imaging Rheumatology bv, Lilly; S. Ramiro, AbbVie/Abbott, Eli Lilly, Galapagos, Merck/MSD, Novartis, Pfizer, UCB, Sanofi; A. Sepriano, UCB, Novartis; A. Molto, Abbvie, UCB, Novartis, Gilead, Pfizer, Lilly, Jannsen.

To cite this abstract in AMA style:

Hamitouche F, Kumaradev S, van der Heijde D, Ramiro S, Sepriano A, Molto A. Determinants of Clinically Important Worsening in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort over 5 Years [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/determinants-of-clinically-important-worsening-in-early-axial-spondyloarthritis-analysis-of-the-desir-cohort-over-5-years/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/determinants-of-clinically-important-worsening-in-early-axial-spondyloarthritis-analysis-of-the-desir-cohort-over-5-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology